Expand SRPT Menu
SRPT MENU

SRPT Latest Press Releases

-- January 26, 2026 --

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients Business Wire 8:00 AM

-- January 23, 2026 --

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy Business Wire 4:05 PM

-- January 12, 2026 --

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues Business Wire 11:58 AM

-- January 7, 2026 --

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease Business Wire 8:30 AM

-- January 5, 2026 --

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 8:30 AM

-- December 31, 2025 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 5:20 PM

-- December 11, 2025 --

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 Business Wire 7:00 AM

-- November 25, 2025 --

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne Business Wire 8:58 AM

-- November 24, 2025 --

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics Business Wire 7:30 AM
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1 Business Wire 7:30 AM

-- November 20, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT PRNewswire 10:00 AM

-- November 14, 2025 --

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information Business Wire 2:54 PM

-- November 3, 2025 --

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE Business Wire 4:05 PM

-- October 27, 2025 --

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results Business Wire 4:05 PM

-- October 23, 2025 --

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF PRNewswire 6:46 AM

-- October 21, 2025 --

Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF PRNewswire 6:46 AM

-- October 3, 2025 --

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress Business Wire 8:30 AM

-- September 30, 2025 --

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 6:00 PM

-- September 24, 2025 --

Kuehn Law Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law Firm PRNewswire 2:10 PM

-- September 5, 2025 --

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year Business Wire 9:00 AM

-- August 29, 2025 --

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action Globe Newswire 3:13 PM
Market Data Delayed 15 Minutes